Historical Archive

PHARMACEUTICAL PRESS REVIEW from 8 to 10 January of AboutPharma

Nerviano Medical Sciences signs an agreement with Genentech

(Il Sole 24 Ore: page 24, Bloomberg Finance & Markets: page 2, Libero Mercato: page 13, la Repubblica: page 47, Corriere della Sera: page 35, la Repubblica Milan: page I – 10 January 2008)

Nerviano Medical Sciences (NMS) has signed a collaboration agreement with Genentech for the research of new anticancer drugs. The operation has a value of 310 million dollars, which will be paid by the US company upon the achievement of certain objectives in the development of laboratory research. Genentech will have the exclusive option to complete the clinical development of the molecules and to put them on the market after having tested them. NMS will be entitled to royalties deriving from the sale of the drugs, if they are placed on the market.



USA: Sanofi-Aventis sues Barr Pharmaceuticals

(Les Echos online – January 10, 2008)

Sanofi-Aventis is suing the generic manufacturer Barr Pharmaceuticals in a New Jersey (USA) court. The French company asks the US Justice to prohibit the marketing of the generic version of the anticancer drug Eloxatin (oxaliplatin) before the patent expires in 2013.



Agreement between Sysmex and BioMérieux

(Les Echos online – January 10, 2008)

The French BioMérieux and the Japanese Sysmex have signed an agreement under which the Japanese company will acquire a stake of 34% in the capital of BioMérieux Japan. The new group, which will be called Sysmex BioMérieux, will be responsible for the promotion and marketing of BioMérieux products in Japan from April 1, 2008.



New biotech freshmen in Piazza Affari

(Il Sole 24 Ore Finance & Markets: page 40, Bloomberg Finance & Markets: page 2 – 10 January 2008)

Yesterday Consob gave its green light for the publication of the prospectus relating to the public offer for admission to listing on the MTA of 25% of the Sienese biotech company Philogen. The debut of the title on Piazza Affari should take place by the end of the month. The go-ahead for the listing of the Milanese biopharmaceutical MolMed should also arrive in January.



"USA: Healthcare 'votes' for the Democrats"

(Il Sole 24 Ore: page 7 – 9 January 2008)

According to UBS Investment Research analysts, if the Democrats return to the White House in November, companies that deal with health care, such as hospitals and homes for the elderly, would be favored. The industries producing generics would also be facilitated, given the intention of the Democrats to facilitate their use to reduce health care costs and those specialized in biotech, especially those involved in stem cell research. Analysts believe Republicans would favor big pharmaceuticals and medical equipment companies instead.



"FDA approves only 19 drugs, the minimum for 24 years"

(Bloomberg Finance & Markets: page 10, Les Echos

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco